Pasithea Therapeutics (KTTA) Other Non-Current Assets (2022 - 2023)
Pasithea Therapeutics (KTTA) posted Other Non-Current Assets of $84703.0 for Q1 2023, down 48.18% sequentially from $163462.0 in Q4 2022.
Pasithea Therapeutics (KTTA) Other Non-Current Assets (2022 - 2023) Analysis & Trends
Pasithea Therapeutics has reported Other Non-Current Assets for 2 years, with the latest figure at $84703.0 in Q1 2023.
- Quarterly Other Non-Current Assets changed N/A year-over-year to $84703.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $84703.0 (changed N/A YoY) and the FY2022 annual result came in at $163462.0, changed N/A from the prior year.
- Other Non-Current Assets declined to $84703.0 in Q1 2023 per KTTA's latest filing, from $163462.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $163462.0 in Q4 2022 and troughed at $84703.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 84,703.00 |
| Dec 31, 2022 | 163,462.00 |